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Abstract 
Research examining variables that influence medication adherence among HIV-positive 
individuals remains an important priority. The patient-provider relationship may influence HIV 
medication adherence, though findings have varied across studies and there is a paucity of 
research examining mechanisms that may account for patient-provider influences on adherence. 
One potential mechanism that may explain this relationship is patient’s beliefs about 
medications, specifically how patients weigh the necessity of medications relative to concerns 
about negative side effects. Using data from a sample of 116 HIV patients recruited during 
outpatient care, this study aimed to (a) examine the effect of the patient-provider relationship on 
both adherence and intentional nonadherence; and (b) clarify whether there is an indirect effect 
of this relationship through medication beliefs. Primary study hypotheses were tested using 
bootstrapped mediation models. Results showed that the patient-provider relationship was 
positively associated with adherence but not intentional nonadherence. There was strong support 
for an indirect effect of this relationship through medication beliefs for adherence but not 
intentional nonadherence. This study could inform interventions to improve the patient-provider 
relationship as well as target potentially modifiable patient beliefs about their medications. 
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The Patient-Provider Relationship and HIV Medication Adherence: Indirect Effects of 
Medication Beliefs 
 There are an estimated 1.2 million people living with HIV/AIDS (PLWHA) in the United 
States and more than 36 million worldwide (World Health Organization; WHO, 2016). With 
approximately 40,000 new infections per year in the United States and over 2 million worldwide 
(WHO, 2015), stemming the HIV epidemic remains an important public health priority. Over the 
past decade, the lifespan of those newly infected with HIV has nearly doubled (Samji et al., 
2013) and HIV is now widely considered a manageable chronic condition by physicians and 
public health experts (Deeks, Lewin, & Havlir, 2013). However, strict adherence to highly active 
antiretroviral therapy (HAART) is of critical importance to avoid disease progression and 
prevent viral resistance (Paterson et al., 2000). Despite significant treatment advances, poor 
medication adherence (defined as below 90-95% of prescribed doses) remains common 
(Cambiano, et al., 2010). Indeed, a recent meta-analysis by Ortego & colleagues (2011) found 
that only 62% of those prescribed HAART adhere to recommended guidelines.  
Identifying patient factors that contribute to medication adherence difficulties is of vital 
importance, as poor adherence is associated with lower CD4 counts and a higher viral load 
(Paterson et al., 2000). These factors contribute to the HIV epidemic by increasing HIV 
transmission risk (Attia, et al., 2009) and highlight the importance of treatment as prevention 
guidelines as well as test and treat strategies (WHO, 2016). Substandard adherence may lead to 
the development of drug-resistant HIV strains (Hatano & Deeks, 2007; Rosenbloom, Hill, Rabi, 
Siliciano, & Nowak, 2012), increased risk for opportunistic infections (Swindells et al., 2002), 
and increased risk for virologic failure (Aberg et al., 2013; Paterson et al., 2000). Further, poor 
adherence to one class of drugs that are commonly used in HAART regimens, Non-Nucleoside 
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Reverse Transcriptase Inhibitors (NNRTI’s) can lead to cross-resistance of the entire NNRTI 
class of drugs (Li et al., 2005; Parienti, et al., 2004). Given the role of adherence in predicting 
treatment success, researchers have emphasized the importance of identifying potentially 
modifiable factors that influence adherence (Beach et al., 2006). 
Research has identified a number of patient-specific factors associated with adherence 
among PLWHA. For example, social support and adherence self-efficacy are positively 
associated with adherence, while depressive symptoms, current substance use, and HIV-related 
stigma have been found to be negatively associated with adherence (Langebeek et al., 2014). 
Although patient and treatment related variables have been studied extensively among PLWHA, 
one risk factor that has received attention in recent years concerns the relationship between 
patients and their treatment teams, and more specifically the patient-provider relationship (Beach 
et al., 2006). The quality of the patient-provider relationship has been shown to improve 
adherence among chronic disease patients (Stange et al., 2010), and recent data suggests that 
specific components of the patient-provider relationship may play a role in HAART adherence 
(Langebeek et al., 2014). Interest in the role of patient-provider relationships and adherence 
among PLWHA is in keeping with growing recognition of the importance of patient-provider 
relationships across all of health care (Swick et al., 1999).  
Among PLWHA, the advent of HAART and the prospect of long term survival enhanced 
the importance of collaborative patient-provider interactions, where patients make decisions 
alongside their providers (Wagner et al., 2005). Accordingly, research has focused on 
understanding the impact of several aspects of the patient-provider relationship on adherence, 
including provider trust, communication, disease-specific information, collaboration, and 
satisfaction (Ironson, Lucette, & McIntosh, 2015; Schneider, Kaplan, Greenfield, Li, & Wilson, 
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2004). While a number of studies have documented the importance of the patient-provider 
relationship as a determinant to medication adherence among PLWHA (Beach et al., 2006; 
Oetzel et al., 2015; Langebeek et al., 2014), other studies have failed to find an association 
between the patient-provider relationship and adherence (Moralejo, et al., 2006; Holmes et al., 
2007; Kalichman, Ramachandran, & Catz, 1999), and one study found that better provider 
communication and interpersonal skills predicted poorer adherence (Ingersoll & Heckman, 
2005). Further, only a few studies have sought to identify factors that may clarify mechanisms 
linking aspects of the patient-provider relationship to adherence.  
Whereas a lack of trust, or a poor relationship with one’s provider may undermine 
engagement in healthcare generally, the impact of the patient-provider relationship on adherence 
may be explained in part by the influence of the patient-provider relationship on beliefs about 
medications. Medication beliefs have been shown to negatively impact treatment adherence 
(Nozaki et al., 2013). Horne and colleagues (1999) developed an approach to explain non-
adherence that emphasizes patient’s beliefs about the necessity of medications and concerns 
related to negative effects of medications. Specifically, the extent to which patients rate their 
need for medication relative to their concerns about medication, operationalized as a differential 
score, is a strong predictor of medication adherence across chronic health conditions, including 
HIV (Horne et al., 2013). Preliminary findings suggest that the association between the patient-
provider relationship and adherence may be partially explained by medication beliefs (Altrice et 
al., 2001; Gauchet et al., 2007). 
The present study aimed to clarify the effect of provider trust and satisfaction on 
medication adherence and examine the role of patient beliefs as a potential mechanism linking 
the patient-provider relationship to adherence. Hypotheses were generated based on the past 
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findings concerning the effect of the patient-provider relationship on HAART adherence and 
research pointing to the role of medications beliefs as a mechanism for explaining the effect of 
the patient-provider relationship on adherence.  
Patient-Provider Relationship among PLWHA 
The patient-provider relationship in HIV care first received attention during the late 
1990’s in a series of qualitative studies that documented how provider knowledge, interpersonal 
skills, and personalized-care were often described as contributing to better adherence (Bakken et 
al., 2000; Roberts 2000). Trust in one’s providers is considered a cornerstone of modern 
medicine, as care is presumed to be optimized when patients trust their provider to have their 
best interest in mind (Hall, Dugan, Zheng, & Mishra, 2001). Trust is especially important as 
many PLWHA report experiencing stigma (Lowther, Selman, Harding, & Higginson, 2014), 
including a significant minority who report stigmatizing experiences in healthcare settings 
(Naughton & Vanable, 2013; Nyblade, et al., 2009). Further, medical mistrust, which includes 
mistrust of one’s provider, is especially high among men who have sex with men (MSM) and 
African-American communities, two groups that are especially vulnerable to HIV infection 
(Halbert, Armstrong, Gandy, & Shaker, 2006; Santos et al., 2013).  
Among PLWHA, provider trust, which includes honesty, fidelity, and confidentiality, has 
generally been associated with better adherence across numerous qualitative and quantitative 
studies (Hall et al., 2001). Indeed, one recent meta-analysis (Langebeek et al., 2014) found that 
both provider trust and satisfaction was associated with better adherence. However, the included 
studies varied considerably in their measurement of the patient-provider relationship and pooled 
trust and satisfaction together. Other researchers consider these distinct variables, as trust 
involves a level of risk in the decision to be vulnerable with another person (Blackstone et al., 
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2012; Thom & Campbell, 1999). Among cross-sectional studies, low provider trust has been 
linked to poorer medication adherence among PLWHA in prison settings (Altice, Mostashari, & 
Friedland, 2001), urban HIV clinics (Blackstock et al., 2012), Southern Infectious Disease (ID) 
clinics (Whetten et al., 2006), and among African HIV clinics (Watt et al., 2010). In contrast, 
Holmes and colleagues (2007) found that among 116 HIV positive patients, provider trust was 
not associated with adherence over a 12-month period. Despite some mixed findings, these 
results suggest that provider trust may play a key role in adherence outcomes. However, there is 
a significant lack of empirical data on the mechanisms that may help to explain the ways in 
which provider trust enhance or diminish medication adherence. 
Another widely studied factor is provider satisfaction, which refers to a patient’s 
appraisal of the services received based on interactions with their provider (Crow, Gage, 
Hampson, & Hart, 2003). A number of studies have investigated the influence of provider 
satisfaction on adherence, with mixed results. For example, provider satisfaction has been 
associated with better adherence in a sample of outpatients from both the United States 
(Schneider et al., 2004) and Canada (Godin et al., 2005). In contrast to these findings, several 
studies have failed to find a direct relationship between satisfaction and adherence. For example, 
provider satisfaction was not associated with adherence in outpatients from Sweden 
(Schonnesson et al., 2006), Spain (Moralejo et al., 2006), and rural areas throughout the United 
States (Cosio, et al., 2010). Among studies examining provider satisfaction and adherence, only 
one examined potential mediators of this association. DiIorio and colleagues (2009) found a 
positive relationship between patient satisfaction and adherence, and their final model showed 
that provider satisfaction indirectly influenced adherence through self-efficacy and depression. 
Taken together, findings provide only mixed support for the impact of provider satisfaction on 
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adherence and only limited data on potential mediating variables that may explain this 
relationship.  
Research is needed to clarify the extent to which patient-provider variables influence 
patient behavior, as is research that clarifies potential mechanisms to explain these relationships. 
One possible mechanism linking provider relationship variables to adherence is the impact that 
the patient-provider relationship may have on patient’s medication beliefs. An understanding of 
the interconnection between the patient-provider relationship and patient’s medication beliefs has 
the potential to improve adherence focused interventions (Beach et al., 2015).  
Testing the Indirect Effect of Medication Beliefs in the  
Patient-Provider to Adherence Relationship 
 Given the importance of patient-provider relationships in HIV care, research is needed to 
clarify the role of specific patient-provider relationship variables on adherence and to clarify 
psychological factors that may explain the ways in which provider level variables shape health 
behavior outcomes. It is conceivable that patient-provider relationships affect adherence by 
simple virtue of the fact that doctors instruct patients to take medicine as prescribed. Effective 
patient education leads to medication taking behaviors, and the extent to which patients follow 
through with instructions would depend primarily on the clarity of the patient education.  
Researchers have proposed a second possibility, namely that the strength of the patient-provider 
relationship influences adherence levels in so far as relationship factors help to solidify patient’s 
beliefs about the need for medication. For example, if a patient trusts their providers, they may 
be more likely to internalize statements made about the importance of taking medication as 
prescribed as a means of maintaining health. On the other hand, if a patient does not trust their 
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providers, they may believe their providers are attempting to minimize the actual side effects of a 
medication. In turn, these beliefs about medications may influence a patient’s adherence.  
The present study tested the hypothesis that patient’s beliefs about the necessity of 
medication and concerns about side effects will mediate the effect of the patient-provider 
relationship on adherence. This perspective is in keeping with that which is proposed by the 
Necessity/Concerns Framework (Horne et al., 2004). Drawing from self-regulation theory, 
Reynolds (2003) proposed a self-regulatory model to explain the numerous factors involved in 
adherence behavior in patients with chronic illness. Self-regulation theory (Diefenbach & 
Leventhal, 1996; Leventhal et al., 1997) suggests that people develop a representation of their 
illness based on background experiences such as their relationship with their providers, as well 
as the method of treatment (e.g., medication). While complex in nature, research has 
demonstrated that beliefs about medications fall under two categories: perceptions related to the 
necessity of a medication and concerns about adverse side effects (Horne et al., 2004; Horne, 
Weinman, & Hankins, 1999). A key consideration in this theory is the importance of the 
differential between the necessity and concerns beliefs. For example, a patient who believes their 
medications are not important to their long-term health and report several concerns related to 
side effects may be less likely to take their medications as prescribed. One recent meta-analysis 
(Horne et al., 2013) identified these two factors as a strong predictor of adherence among 
PLWHA. Given that providers play a critical role in educating patients by addressing concerns 
and emphasizing the necessity of medications (Altice, Mostashari, & Friedland, 2001), it is 
possible that beliefs about medications can explain the effect of the patient-provider relationship 
on medication adherence.  
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To date, only one study has investigated the role of both necessity and concerns related to 
medications as a mediator of the association between patient-provider relationships and 
medication adherence. Gauchet, Tarquinio, and Fischer (2007) used a structural equation 
modeling approach to evaluate the relationship between HIV patients’ confidence in their 
provider, beliefs about medication and adherence. Their results showed higher provider 
confidence predicted greater adherence, and this relationship was partially mediated by patients’ 
beliefs in the necessity of HIV medications, but not concerns about medication side-effects. 
Conceptually, this suggests that patients’ beliefs about the necessity of their medications are 
influenced by interactions with their provider. The authors tested an additional model where 
beliefs about medications and provider confidence were reversed. That is, beliefs about 
medications predicting medication adherence, mediated by provider confidence. Importantly, the 
fit was less optimal, suggesting that confidence in the provider is influencing patients’ beliefs 
about their medication, and not the other way around. Results from this study are consistent with 
the notion that patients’ medication beliefs are formed, in part, by the confidence ascribed to 
interactions with their health care provider.  
The study by Gauchet and colleagues (2007) has several limitations. First, the study 
evaluated only one aspect of the patient-provider relationship (confidence). There is evidence 
from meta-analytic work that other aspects of the patient-provider relationship, such as trust and 
satisfaction are relevant to medication adherence (Langebeek et al., 2014). Second, the authors 
used the original 18-item Beliefs about Medicines Questionnaire (BMQ) and related four 
subscales (Specific-Necessity, Specific-Concerns, General Overuse, General Harm) rather than 
the HIV-specific BMQ-HAART. In their final model, they included three additional variables 
related to values which may have confounded their results. Further, previous research has found 
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that the interaction between necessity beliefs and concerns is a stronger predictor of adherence 
than either variable alone (Horne et al., 2004). Specifically, Horne and colleagues (2004) found 
that patients were more likely to report lower adherence if their concerns about medications were 
high relative to their perception of the necessity of HAART. Finally, the authors used a measure 
of adherence that created a total medication adherence score. This methodology fails to capture 
more deliberate decisions to skip or alter doses, which can be classified as intentional 
nonadherence (Wroe, 2002). Several studies in HIV-infected patients have found rates of 
intentional nonadherence from 11%-20% (Heath et al., 2002; Mo & Mak, 2009). Further, Norton 
and colleagues (2010) found that patients who reported intentionally skipping doses were more 
likely to report difficulty talking to their health care provider. Thus, intentional nonadherence 
may reflect a poor patient-provider relationship and including such a measure will allow better 
understanding of the mechanisms involved.  
Current Study 
The current study aimed to clarify the association between the patient-provider 
relationship as measured from the patient’s perception, and HAART adherence using the 
Necessity/Concerns Framework. First, this study examines the effect of provider trust and 
satisfaction on adherence and intentional nonadherence. It was hypothesized that both provider 
trust and satisfaction will be positively associated with overall medication adherence levels and 
negatively associated with engagement in intentional nonadherence. Next, this study examines 
the ability of the Necessity/Concerns Framework to explain the association of provider trust and 
satisfaction on adherence. It was hypothesized that there will be an indirect effect of the patient-
provider to adherence relationship through medication beliefs, as measured by the necessity-
concerns differential, (i.e., difference between perceived necessity of medications relative to 
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concerns about medications, see Figure 1). Specifically, patients who report more positive 
relationships with their providers will endorse more necessity beliefs relative to concerns beliefs 
which will in turn lead to increased medication adherence and decreased engagement in 
intentional nonadherence. Those patients who report poor relationships with their providers will 
endorse more concerns beliefs relative to necessity beliefs which will lead to decreased 
medication adherence and increased engagement in intentional nonadherence.  
 This study is the first to investigate the effect of the patient-provider relationship on both 
adherence and intentional nonadherence in a sample of PLWHA while examining the role of 
medication beliefs as defined by the Necessity/Concerns Framework. The results from this study 
will help to elucidate malleable factors that can be targeted by interventions aimed at providers 
or patients. Study hypotheses were tested using data from 116 patients participating in a study 
examining barriers to health and coping in the context of HIV care (see Littlewood and Vanable, 
2013).   
Methods 
Participants 
A total of 150 participants from Upstate New York (41% female, 57% male, 2% 
transgender) were recruited for study participation during an outpatient HIV care visit. For the 
present study, participants were required to be current HAART users, bringing the final sample 
size to 116. The average age was 44 years old (range 19-64). 48% of participants self-identified 
as African-American, 41% as Caucasian, 6% as Multi-Racial, 4% as Native American, and 1% 
as Pacific Islander. The average time elapsed since HIV diagnosis was 11 years and 59% of our 
sample reported their viral load was currently “undetectable” (viral load <50). The majority of 
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participants were unemployed (62%), 19% of participants did not have a high school diploma, 
37% had a high school degree, and 43% reported at least some college. 
Procedures 
 Participant recruitment. Participants were recruited during routine outpatient HIV care 
visits. Patients were informed about the opportunity to participate in the study by a clinic staff 
member. Verbal consent to be approached by the research team was obtained by a health care 
provider before a patient was asked about study participation. A second source of study 
participants was through a pool of past study participants who had previously agreed to be 
contacted regarding future studies opportunities. Informed consent was obtained from all 
participants before data collection. Eligible participants were HIV-positive, at least 18 years old, 
currently undergoing HAART treatment, English-speaking, and capable of providing informed 
consent. Participants were compensated $20 upon study completion. 
 Survey administration and data entry. The questionnaires were administered using audio 
computer-assisted self-interviewing (ACASI). ACASI has been shown to increase patient’s 
disclosure of sensitive information over traditional interviews (Schroder, Carey, & Vanable, 
2003). Surveys were completed in a private room and required roughly one hour to complete. 
Survey data was exported to SPSS and merged with medical chart data. All statistical analyses 
were conducted using SPSS v16.0 (Statistical Package for the Social Sciences; SPSS Inc., 
Chicago, IL). 
Measures 
 Demographics. Data obtained from self-report included age, education, income, ethnicity, 
employment status, duration of HIV medication usage, and sexual orientation.   
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HAART adherence. Items assessing HAART adherence were adapted based on research 
conducted by Simoni and colleagues (2006). Self-reported adherence was assessed for the past 
week and past month. For the past week, participants completed a timeline follow back (TLFB) 
for the past seven days. The TLFB asks participants to report the number of pills they are 
supposed to take every day and how many they actually took. From these data, a past-week 
adherence score is calculated (prescribed doses – missed doses) / (prescribed doses) x 100. The 
advantage of assessing adherence for the past week compared to past several days is that a 
weekend will always be included, and previous research has shown adherence is often 
problematic on weekends (Bachhuber et al., 2010). Additionally, these data may allow us to 
differentiate those who are consistently adherent from those who are typically less adherent, but 
have better adherence over shorter periods (Simoni et al., 2006). For the past month, HAART 
users completed a visual analog scale (VAS) ranging from 0-100% where they estimated the 
amount of HIV medications they took. Past month adherence was dichotomized as ≥ 95% or < 
95%, consistent with previous research (Viswanathan et al., 2015). 
Intentional nonadherence since HIV diagnosis. To capture the prevalence of intentional 
nonadherence occurring since the time of diagnosis, 16 items assessed four domains consistent 
with previous research (Laws et al., 2000; Littlewood & Vanable, 2013; Roberts & Mann, 2003): 
(1) Treatment uptake, whereby patients declined to begin taking HAART despite 
recommendations from their physician; (2) treatment interruption, in which patients stopped 
taking some or all of their medications without telling their provider; (3) medication vacation, 
where patients “took a break” of more than one day from some or all of their medications; and 
(4) medication changes, representing any intentional alterations to their HAART regimens (e.g., 
taking less than prescribed, taking a  dose later than scheduled, doubling up on their dosage to 
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make up for a missed dose, or skipping any special instructions). A score of 1 was assigned for 
each category with a positive response, and the sum of these scores yielded an intentional 
nonadherence composite score (range 0-4).  This measure assesses the underlying motivation of 
intentionally nonadherent patients as patients make decisions about treatment based on a wide 
range of factors (Wroe, 2002). 
 Intentional nonadherence, past month. To estimate the extent of intentional nonadherence 
in the past month, participants were asked how often they made changes to their prescribed 
HAART regimens or skipped a dose of their medication for personal reasons (e.g., feeling 
depressed, side effects, change in plans, or other). Participants indicated their response by 
placing a mark on a visual analog scale with anchors (0 = Never, 50 = About half the time, 100 = 
All the time). A single intentional nonadherence score for the past month was calculated by 
taking the average of these items. This measure was included in addition to the previous lifetime 
assessment of intentional nonadherence to ensure answers were based on their current provider 
(e.g., patients may have engaged in different behaviors with a prior provider). 
Beliefs About Medications. To assess patients beliefs about HAART medications, the 
validated Beliefs about Medicines Questionnaire – HAART version (BMQ-HAART) was used 
(Horne et al., 1999). Two subscales were used for the present study: perceived necessity of 
HAART and concerns about potential adverse consequences of using HAART. Items related to 
the perceived necessity of HAART refer to participant’s beliefs that taking HAART is necessary 
for their health and longevity. The necessity subscale consists of 8 items such as “My health 
depends on HIV medications” and “HIV meds can keep me alive”. Items related to concerns 
about adverse consequences refer to both concerns about long term effects of HAART use and 
more tangible concerns such as side effects or embarrassment from medication use. The 
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concerns subscale consists of 11 items such as “My HIV meds give me unpleasant side-effects” 
and “Having to take HIV meds worries me”. Patients were asked to rate their agreement of 19 
statements about HIV medications using a 5-point Likert scale with a range of “strongly agree” 
to “strongly disagree.” Internal reliability for both scales was good (alpha = .70 for necessity and 
.74 for concerns) and is consistent with other samples (Horne et al., 2004).  
Consistent with previous methodology (Horne et al., 2004; Horne et al., 2007), a 
necessity-concerns differential was calculated by computing mean scores for both subscales and 
subtracting concerns scores from necessity scores (range -4: 4). This differential score reflects 
how patients rate the necessity of medication relative to their concerns and has been shown to be 
a stronger predictor of adherence than either subscale alone (Horne et al., 2007). As such, the 
model for the present study will test this differential score as a potential mediator of the patient-
provider to adherence relationship. Higher differential scores reflect patients placing more value 
on the necessity of medication relative to concerns about medication. 
Patient-Provider Relationship. The quality of the patient-provider relationship was 
assessed using 26 items based on previous work by Schneider and colleagues (2004). For the 
present study, the subscales of provider trust (3-items) and provider satisfaction (3-items) were 
of interest. Items related to overall satisfaction with their treatment team (e.g., Overall, how 
would you rate your provider’s personal manner?) were rated on a 5-point Likert scale from 1 
(Poor) to 5 (Excellent). Items related to trust in their treatment team (e.g., I can tell my HIV care 
provider anything, even things that I might not tell anyone else) were rated on a 6-point Likert 
scale from 1 (Strongly Disagree) to 6 (Strongly Agree) while one item (All things considered, 
how much do you trust your HIV care provider?) was rated on a 5-point scale of 1 (Not at all) to 
5 (Completely). Of note, this measure captures the patient’s perception of their relationship with 
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providers. Internal reliability for both subscales in this sample was good (alpha for satisfaction = 
0.96 and for trust, alpha = 0.83) and is consistent with other studies (Schneider et al., 2004). 
Data Analytic Plan 
Power analyses were conducted to determine if the primary hypotheses could be tested 
using this sample of 116 patients with at least the 0.8 minimum statistical power 
recommendation for mediation analyses (Fritz & Mackinnon, 2007).  The only study to test the 
patient-provider to adherence relationship mediated by medication beliefs found a small-medium 
effect of the provider relationship on medication beliefs and a small-medium effect of 
medication beliefs on adherence (Gauchet et al., 2007). Of note, the authors used a different 
measure of the patient-provider relationship and medication beliefs. Nonetheless, these estimates 
were used to guide the current study. The effect of the patient-provider relationship on 
medication beliefs and the effect of medication beliefs on adherence was estimated to be small-
medium. An a-priori sample size calculation suggested a total sample size of 92. The sample size 
of the present study exceeds this sample size; thus, this study has acceptable statistical power. 
All statistical analyses were conducted using SPSS version 16 (SPSS Inc., Chicago, IL). 
First, descriptive statistics were conducted to characterize the sample. Next, bivariate 
correlations were examined for hypothesized associations of the patient-provider relationship, 
beliefs about medications, and both medication adherence and intentional nonadherence. Finally, 
mediation models (see Figure 1) tested the effect of provider trust on the mediator (beliefs about 
medications, a path), the effect of the mediator (beliefs about medications) on both outcomes 
(adherence and intentional nonadherence, b path), and the effects of provider trust on both 
outcomes (adherence and intentional nonadherence, c path). Next, two additional mediation 
models (see Figure 1) tested the effect of provider satisfaction on the mediator (beliefs about 
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medications, a path), the effect of the mediator (beliefs about medications) on both outcomes 
(adherence and intentional nonadherence, b path), and the effects of provider satisfaction on both 
outcomes (adherence and intentional nonadherence, c path).  
To ensure the causal path represents the most viable model fit, several alternative 
mediation models were tested. It may be possible that beliefs about medications influence the 
patient-provider relationship, rather than vice versa. In these models, the necessity-concerns 
differential was entered as the independent variable, and both provider trust and satisfaction 
were entered as mediators in separate models with adherence and intentional nonadherence as 
outcomes.  
Analyses were conducted using an SPPS macro designed to examine mediation models 
using bootstrapping methods (PROCESS; Preacher & Hayes, 2008). The macros provide path 
coefficients for the mediation models and bootstrapped 95% confidence intervals for the indirect 
effect of provider satisfaction and provider trust on both outcomes of adherence and intentional 
nonadherence via beliefs about medications.  
Results 
Descriptive Findings 
As shown in Table 1, participants reported moderate to high levels of trust in and 
satisfaction with their providers (M’s = 4.59 and 4.38 respectively). With regard to medication 
beliefs (the necessity-concerns differential), participants reported a lower number of concerns (M 
= 2.46; SD = .64) relative to necessity beliefs (M = 4.33; SD = .57). On average, participants 
reported taking 92% of their prescribed medications in the previous week and 90% of their 
prescribed medications in the past month. Approximately 90% of patients reported ≥ 95% 
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adherence in the past month. The average rate of intentional nonadherence over the past month 
was 18%.   
Association of Trust and Satisfaction to Adherence 
 The first set of analyses examined the hypothesis that both provider trust and satisfaction 
would be positively associated with medication adherence and negatively associated with 
intentional nonadherence. Consistent with this hypothesis, provider trust was positively 
associated with past week adherence (r = .34, p < .05; Table 2) and past month adherence (r = 
.18, p = < .05). Provider satisfaction was also positively associated with past week adherence (r = 
.21, p < .05) and past month adherence (r = .23, p < .05). Provider trust was negatively associated 
with past month intentional nonadherence (r = -.24, p < .05) but was not associated with lifetime 
intentional nonadherence. Provider satisfaction was not associated with either past month 
intentional nonadherence or lifetime intentional nonadherence. 
 Tests of the indirect effect of medication beliefs on 7 Day and 30-Day Adherence  
Tables 3 and 4 provide comprehensive statistical information for each model. Path results 
common to multiple models are reported only in the first model in which they appear. For all 
models, covariates of age, gender, and time on HAART were included, as these factors have 
been linked with poorer adherence (Beer & Skarbinski, 2014). 
A major goal of this study was to test the hypothesis that there would be an indirect effect 
of provider trust on adherence via beliefs about medications. Regression analyses established 
that provider trust was not associated with past 30-day adherence while beliefs about 
medications trended toward significance (b: β = .372; z = 1.905; p = .057). Based on 10,000 
bootstrap re-samples, the indirect effect of provider trust on 30-day adherence via mediation 
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beliefs was positive and significant (Table 4: OR = .184; SE = .990; 95% CI: .251 to 4.14).   The 
model with 7-day adherence as the dependent variable was not significant. 
The next model replaces provider trust with provider satisfaction, variables that are 
moderately correlated with one another (r = .65, p < .001). Provider satisfaction was not 
associated with 7-day adherence in the model but was associated with medication beliefs (a: β = 
0.289; t = 2.855; p < .01). Medication beliefs and 7-day adherence were positively associated (b: 
β = 3.331; t = 2.312; p = 0.023). Based on 10,000 bootstrap re-samples, there was a significant 
positive indirect effect of provider satisfaction on 7-day adherence via medication beliefs (Table 
4: β = .961; SE = .634; 95% CI: .126 to 2.71). Given that adherence may vary on a week-to-week 
basis, the model was tested again with 30-day adherence as the outcome. Regression analyses 
established that provider satisfaction was not associated with 30-day adherence while medication 
beliefs was positively associated with 30-day adherence (b: OR= .442; z = 2.351; p = .019). 
Based on 10,000 bootstrap re-samples, there was a significant positive indirect effect of provider 
satisfaction on 30-day adherence via medication beliefs (Table 4: β = .127; SE = .084; 95% CI = 
.021 to .344).  
Indirect Effect of Medication Beliefs in Relation to Intentional Non-Adherence  
A second primary goal of the present study was to test whether there is an indirect of the 
patient-provider to adherence relationship through medication beliefs. It was hypothesized that 
the patient-provider to intentional nonadherence relationship would be partially influenced by 
medication beliefs such that better patient-provider relationships would lead to a higher 
necessity-concerns differential, and lower engagement in intentional nonadherence. To examine 
this hypothesis, the previous models were run replacing the outcome of medication adherence 
with intentional nonadherence. Based on 10,000 bootstrap re-samples, the indirect effects of 
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provider trust on both measures of intentional nonadherence through medication beliefs were not 
significant. Model 4 (Table 3) tests the indirect effect of provider satisfaction to intentional 
nonadherence through medication beliefs. There was a significant negative indirect effect of 
provider satisfaction on lifetime intentional nonadherence via beliefs about medications (Table 4: 
β = -.056; SE = .036; 95% CI: -.153 to -.004). Regression analyses established that provider 
satisfaction was not associated with lifetime intentional nonadherence while medication beliefs 
(b: β = -.195; t = -1.977; p = .05) was associated with lifetime intentional non-adherence. Neither 
model with past 30-day intentional nonadherence as the outcome was significant.  
Alternative Models 
Given the possibility that beliefs about medications influence the patient-provider 
relationship, rather than vice versa, several alternative models were examined (Table 4). 
Medication beliefs were entered as the independent variable and both provider trust and 
satisfaction were entered as mediators in separate models. In these models both past week and 
past month adherence, as well as past month and lifetime intentional nonadherence were entered 
as the dependent variables. All models with provider satisfaction as the mediator were not 
significant. However, the indirect effect of medication beliefs to past week adherence via 
provider trust achieved significance (β = 1.731; SE = 1.101; 95% CI: .232 to 4.86).   
 Given the use of a difference score as a mediator, additional models were run with both 
necessity beliefs and concern beliefs entered in parallel. Results confirmed a significant indirect 
effect of provider trust to past 30-day adherence via medication beliefs (β = .194; SE = .148; 
95% CI: .012 to .604). The necessity beliefs path was significant (β = -.226; SE = .163; 95% CI: 
-.012 to .604) but the concern beliefs path was not.  Additional models were not significant. 
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These results confirm that the necessity-concerns difference score provided a more sensitive test 
of the hypotheses in this study.  
Discussion 
 The present study is the first to examine the indirect effect of the patient-provider 
relationship on both HIV medication adherence and intentional nonadherence through 
medication beliefs. Findings from this sample of 116 HIV-infected adults provide support for the 
importance of patients’ beliefs about medications in the patient-provider to adherence 
relationship. In keeping with the first major hypothesis, provider trust and satisfaction showed 
positive associations with both adherence outcomes. Contrary to predictions, the hypothesized 
association of patient-provider relationship to intentional nonadherence was largely not 
supported. Only provider trust was negatively associated with past month intentional adherence, 
and not lifetime intentional nonadherence. Provider satisfaction was unrelated to both intentional 
nonadherence outcomes.  
The primary aim of this study was to examine the role of patient’s medication beliefs in 
the patient-provider to adherence relationship. The second major hypothesis, that there would be 
a significant positive indirect effect of the patient-provider relationship to adherence through 
medication beliefs received strong support, particularly in the context of provider satisfaction. 
Study findings confirmed an indirect effect of provider satisfaction and both general adherence 
outcomes via medication beliefs. Thus, findings provide preliminary evidence that a patient’s 
level of satisfaction with and trust in their providers influences whether they internalize the 
information provided by the providers, and that information may in turn influence decisions 
about adherence.  
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With regard to provider trust, there was a significant indirect effect for past month, but 
not past week adherence through medication beliefs. An alternative model with provider trust as 
the mediator found an indirect effect of medication beliefs to past month and past week 
adherence via provider trust. This finding raises the possibility that patient’s medication beliefs 
also influence a patient’s perception of their providers. One possibility is that if a patient’s 
preconceived medication beliefs are congruent with the message from their providers, the patient 
is more likely to adhere to their medications. When the message received by patients is at odds 
with their beliefs, the patient may feel dissatisfied with their care or distrustful of their providers 
leading to poorer adherence. Negative medication beliefs may also reflect a more general 
skepticism or distrust of healthcare. Longitudinal data are needed to confirm the directionality of 
these effects.  
An important and understudied area of HIV behavioral research concerns the role of 
intentional nonadherence, where volitional decisions by patients are made to alter their 
medication regimen. These deliberate decisions are a related yet separate phenomena from 
adherence which has led some to hypothesize they may be a product of a poor patient-provider 
relationship (Norton et al., 2010). In this study, it was hypothesized that a better patient-provider 
relationship would lead to more positive medication beliefs, and in turn less engagement in 
intentional nonadherence. In this sample, only provider satisfaction to lifetime intentional 
nonadherence through medication beliefs was significant. Provider trust was largely unrelated to 
intentional nonadherence. Of note, lifetime intentional nonadherence may reflect experiences 
with previous providers or older classes of HIV medication which have poorer adherence rates 
(e.g., Heath et al., 2002). Given the relative lack of association between study variables with 
intentional nonadherence, a spurious finding cannot be ruled out.  
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For PLWHA, a variety of patient-specific factors influence medication adherence, 
including adherence self-efficacy, substance use, depressive symptoms, social support, and 
demographic factors (Langebeek et al., 2014). The present research expands beyond a focus on 
individual level factors to consider the influence of patient perceptions of their provider in 
relation to medication adherence. Future research can extend the present findings by considering 
the role of patient-provider influences within a broader framework of both individual, contextual, 
and dyadic factors related to adherence.  Self-regulation models provide a unifying framework 
that allows for a better understanding of how multiple factors interact to influence an individual’s 
understanding of their illness and subsequent health behaviors related to treatment (Levanthal et 
al., 1997). According to self-regulation theory, patient’s construct schemas about their illness 
based on factors such as culture, previous experience, and interactions with others, including 
their healthcare providers. A better understanding of the interplay among these variables can aid 
in our understanding of how patient-provider relationships influence adherence within the 
broader context of the multitude of factors that have been linked with adherence and related 
outcomes.  
Overall, while additional work is needed, this study points to the potential importance of 
dialogue between patients and providers. The quality of the patient-provider relationship sets the 
stage for patient education by building trust and shared satisfaction. With an increasingly cost-
driven environment where providers face-to-face time with patients is often limited, providers 
are challenged to build rapport and efficiently communicate with their patients. Although more 
research is needed, these initial findings point to the possibility that medical training should 
emphasize the development of communication skills in addition to medical expertise. It may also 
be beneficial for healthcare organizations to assess patient’s perceptions of their providers, 
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particularly in the context of chronic illness which require high levels of medication adherence.  
Such feedback, where low trust or satisfaction is evident, can help organizations and providers 
improve patient outcomes through interventions aimed at improving doctor-patient relationships. 
This study has several limitations, the first being the modest sample size and cross-
sectional nature of these data which precludes causal inference. Although these findings point to 
the possibility that patient-provider relations influence beliefs rather than vice-versa, longitudinal 
data would help provide clearer evidence of the temporal sequencing of these effects. Our 
sample was recruited from an outpatient IV clinic; researchers are encouraged to examine these 
findings in underserved communities such as rural areas or individuals without consistent care 
(e.g., Stepleman, et al., 2006). Additionally, this project framed provider trust and satisfaction as 
separate variables. It may be that a model that includes both variables simultaneously or controls 
for one another is a better fit for these data. It is possible that provider trust and satisfaction 
reflect a more general attitude toward their providers rather than separate but related constructs. 
Future research should test such models to determine if they better explain the relationship 
between these variables.  
Strengths of this study include a demographic makeup that is representative of PLWHA 
at large and is consistent with other samples of outpatient HIV patients (e.g., Beach et al., 2013; 
Cambiano et al., 2010). Methodologically, this study used a well-established measure of 
medication beliefs (Horne et al., 2013) and two previously developed measures of adherence and 
intentional nonadherence. This study’s inclusion of intentional nonadherence is novel and adds 
to the paucity of literature on this variable.  
In conclusion, the results of the present study suggest that one mechanism through which 
the patient-provider relationship influences medication adherence may be patients’ beliefs about 
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their medications. These data provide preliminary evidence that the quality of a patient’s 
perceived relationship with their providers and their beliefs about medications are relevant 
factors that exert an influence on HIV medication adherence and may be useful predictors of 
adherence. Providers are encouraged to focus attention on building strong rapport, trusting 
relationships and overall satisfaction to set the stage for effective patient education. Ensuring 
they educate patients about the necessity of taking medication and alleviating any concerns may 
improve patient outcomes and health. 
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Figure 1. Conceptual model. The effect of provider trust and provider satisfaction on Adherence 
(Y1) and Intentional nonadherence (Y2) with beliefs about medications (Necessity/Concerns 
differential) as a mediator.  
Adherence (Y1) 
Intentional non-
adherence (Y2) 
Necessity - Concerns 
Provider Trust  
Provider 
Satisfaction 
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Table 1. Demographic and Summary Statistics  
Note: n = 116. 
 
 
 
 
 
 
Variable (n) (%) M SD 
Age (years)   45.35 8.60 
 Less than High School 
 High School diploma  
 Some College or Degree 
22 
41 
53 
19 
35.3 
20.5 
  
Gender 
 Male 
 Female 
 Transgender 
 
67 
47 
2 
 
57.8 
40.5 
1.7 
  
Race 
 African American 
 White 
 Multiracial or Other 
 
50 
54 
12 
 
43.1 
46.6 
10.3 
  
Currently Employed 44 37.9   
Provider Trust   4.59 .86 
Provider Satisfaction   4.38 1.01 
Necessity/Concerns   2.24 1.13 
Necessity   4.33 .57 
Concerns   2.46 .64 
Past Week Adherence  92.48   
Past Month Adherence  89.70   
Lifetime Intentional 
Nonadherence* 
  2.04 1.16 
Past Month Intentional 
Nonadherence  
 17.69   
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Table 2. Bivariate Correlations Between Primary Variables 
Variable 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 
1.Trust -          
2.Satisfaction .65* -         
3.Necessity/Concerns .39* .26* -        
4.Necessity .35* .04 .74* -       
5.Concerns -.26* -.34* -.80* -.19* -      
6.Past week adherence .34* .21* .26* .18 -.22* -     
7.Past month adherence .18* .23* .23* .25* -.12 .36* -    
8.Intentional – Lifetime -.08 -.05 -.19* -.13 .16 -.14 -.41* -   
9.Intentional – past 30-day -.24* -.13 -.17 -.20* .08 -.53* -.46* .25* -  
Note: Correlations represent Pearson’s r, * p < .05, Past month adherence: 0 = ≤ 95%, 1 = ≥ 
95%. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
28 
 
 
 
Table 3. Path Results for Simple Mediation Models. 
Model 1. Trust → BMQ → Adherence B SE T P value 
(a) Trust → BMQ  0.610 0.108 5.655 <.001** 
(b) BMQ → Adherence past week 1.690 1.528 1.106 0.271 
(c’) Trust → Adherence past week 6.309 1.991 3.168 .002** 
(b) BMQ → Adherence past month .372 .195 Z: 1.905 .057 
(c’) Trust → Adherence past month .266 .253 Z: 1.052 .293 
Model 2. Satisfaction → BMQ → Adherence B SE T P value 
(a) Satisfaction → BMQ 0.289 0.101 2.854 0.005** 
(b) BMQ → Past week 3.331 1.441 2.312 0.023* 
(c’) Satisfaction → Past week 2.707 1.610 1.681 0.095 
(b) BMQ → Past month .442 .188 Z: 2.351 .019* 
(c’) Satisfaction → Past month .014 .198 Z: .069 .945 
Model 3. Trust → BMQ → Intentional 
Nonadherence  
B SE T P value 
(b) BMQ → Past month  -1.855 2.067 -.897 .372 
(c’) Trust → Past month -4.534 2.691 -1.685 .095 
(b) BMQ → Lifetime -.183 .108 -.1701 .092 
(c’) Trust → Lifetime -.030 .140 -.217 .829 
Model 4. Satisfaction → BMQ → Intentional 
Nonadherence 
B SE T P value 
(b) BMQ → Past month  -3.023 1.912 -1.581 .117 
(c’) Satisfaction → Past month -1.936 2.128 -.910 .365 
(b) BMQ → Lifetime -.195       .099 -1.977  .05* 
(c’) Satisfaction → Lifetime .003 .110 .026 .979 
Note: * p < .05, ** p < .01. BMQ = Beliefs about Medicines questionnaire. 
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Table 4. Bootstrap Estimates of the 95% CIs for the Indirect Effects. 
Indirect effects OR B SE CI (LB) CI (UB) 
Adherence      
1a Trust → BMQ → 7-day Adhere - 1.169 .872 -.197 3.429 
1b Trust → BMQ → 30-day Adhere .184 - .990 .251 4.140 
2a Satisfaction → BMQ → 7-day Adhere - .961 .634 .126 2.710 
2b Satisfaction → BMQ → 30-day Adhere .127 - .084 .021 .344 
Intentional Nonadherence      
3a Trust → BMQ → Past month - -.989 1.073 -3.155 .966 
3b Trust → BMQ → Lifetime - -.099 .064 -.262 .004 
4a Satisfaction → BMQ → Past month  - -.854 .667 -2.630 .104 
4b Satisfaction → BMQ → Lifetime  - -.056 .036 -.153 -.004 
Alternative Models      
BMQ → Trust → Past Month  1.731 1.101 .232 4.860 
Trust → Necessity & Concerns → Past Month  .194 .148 .012 .604 
Note: CI (LB) and CI (UB) represent the lower and upper bound of a 95% bootstrapped 
confidence interval with 10,000 resamples. BMQ = Beliefs about Medicines questionnaire. 
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Appendix A. 
Patient-Provider Relationship Scale 
Tinst1. We are interested in your relationship with your HIV care providers. The following 
questions ask about your relationship with the providers who are most involved in your HIV 
care. For example, the people who talk to you about how to take meds or get you started on 
meds; or the people who see you when you have an emergency. Remember, your responses will 
not be shared with any of your providers. We want to know how you truly feel about your HIV 
care providers. 
 1  Poor 
 2  Fair 
 3  Good 
 4  Very Good 
 5  Excellent 
How are your HIV care providers at…  
Overall Communication 
T1. …explaining the results of tests in a way that you understand? 
T2. …giving you facts about the benefits and risks of treatment? 
T3. …telling you what to do if certain problems or symptoms occur? 
T4. …demonstrating caring, compassion, and understanding? 
T5. …understanding your health worries and concerns? 
HIV-specific Information 
T6. …talking with you about your sex life? 
T7. …asking about stresses in your life that may affect your health? 
T8. …at asking about problems with alcohol? 
T9. …at asking about problems with street drugs like heroin and cocaine? 
Adherence    
T10. …giving you information about the right way to take your HIV medicines? 
T11. …understanding the problems you have in taking your HIV medicines? 
T12. …helping you solve problems you have taking your HIV medicines the right way? 
Participatory Decision-making 
T13. How often do your HIV care providers ask you to take some of the responsibility for your 
treatment? 
 1  Never 
 2  Rarely 
 3  Sometimes 
 4  Often 
 5  Very often 
T14. If there was a choice between treatments, would your provider ask you to help make the 
decision? 
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 1  Definitely Not 
 2  Probably Not 
 3  Uncertain 
 4  Probably Yes 
 5  Definitely Yes 
T15. How often do your HIV care providers make an effort to give you some control over 
treatment decisions? 
 1  Never 
 2  Rarely 
 3  Sometimes 
 4  Often 
 5  Very often 
T16. How often do your HIV care providers offer choices in your medical care? 
T17. How often do your HIV care providers discuss the pros and cons of each treatment option 
with you? 
T18. How often do your HIV care providers get you to state which treatment option you would 
prefer? 
T19. How often do your HIV care providers take your preferences into account when making 
treatment decisions?  
 1  None of the time 
 2  A little of the time 
 3  Some of the time 
 4  Most of the time 
 5  All of the time 
Overall Satisfaction with Provider 
 1  Poor 
 2  Fair 
 3  Good 
 4  Very Good 
 5  Excellent 
T20. Overall, how would you rate your provider’s personal manner (e.g., courtesy, respect, 
sensitivity, friendliness)? 
T21. How would you rate your provider’s communication skills (e.g., listening carefully, 
answering questions, giving clear explanations)? 
T22. How would you rate your provider’s technical skills (e.g., thoroughness, carefulness, 
competence)?  
 
Trust in Provider 
Tinst2. Thinking about how much you trust your HIV care provider, how strongly do you agree 
or disagree with the following statements? 
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 1  Strongly Disagree 
 2  Disagree 
 3  Somewhat disagree 
 4  Somewhat agree 
 5  Agree 
 6  Strongly Agree 
 
T23. I can tell my HIV care provider anything, even things that I might not tell anyone else. 
T24. My HIV care provider cares more about holding down costs than about doing what is 
needed for my health. 
T25. My HIV care provider cares as much as I do about my health. 
T26. All things considered, how much do you trust your HIV care provider? 
 1  Not at all 
 2  Only a little 
 3  Somewhat  
 4  Quite a bit 
 5  Completely  
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Appendix B. 
Beliefs about Medications Questionnaire 
Rinst1. Next, you will hear statements that other people living with HIV have made about HIV 
meds. Please tell us how much you AGREE or DISAGREE with each statement be checking the 
response that best fits for you. There are no right or wrong answers. Please tell us how you really 
feel about medications for HIV. 
 1  Strongly Disagree 
 2  Disagree 
 3  Somewhat disagree 
 4  Somewhat agree 
 5  Agree 
 6  Strongly Agree 
C  R1. My HIV meds give me unpleasant side-effects. 
N  R2. My health depends on HIV medications. 
C  R3. Taking HIV meds is embarrassing.  
N  R4. Without HIV meds, I would become very ill. 
N  R5. My health in the future will depend on HIV medications. 
C  R6. HIV medications are a mystery to me. 
N  R7. HIV medications keep HIV under control. 
N  R8. HIV meds can keep me alive. 
C  R9. Having to take HIV meds worries me. 
C  R10. I sometimes worry about the long-term effects of HIV medications. 
C  R11. HIV medications disrupt my life. 
N  R12. Missing HIV medications for a day won’t matter in the long run. (R) 
C  R13. I sometimes worry about becoming too dependent on HIV medications. 
C  R14. I am unlikely to get a bad side-effect from my meds in the next month. (R) 
N  R15. HIV meds are my best hope for the future. 
C  R16. Taking HIV meds has been much worse than I expected. 
C  R17. I have received enough information about HIV medications. (R) 
N  R18. My life would be impossible without HIV meds. 
C  R19. The taste of my meds makes me feel unwell. 
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Appendix C. 
Intentional Nonadherence 
 
Instructions 
The next questions will ask about your HIV meds. We understand that there are many challenges 
to taking HIV medications and many people struggle to take their pills as prescribed. Some 
people find it hard to take their pills according to all the special instructions. Some people get 
busy and forget to carry their pills with them and others decide to skip doses to avoid side effects 
or to just not be taking pills that day. Telling us about your actual experiences with HIV meds 
will help us to get a better understanding of what is needed to improve HIV care. So please 
answer honestly and do not worry about telling us that you don't take your pills perfectly, your 
answers are completely confidential. 
 
People have different experiences regarding the decision to start taking HIV medications. Please 
take a moment to think about your own experience deciding to start taking HIV medications. 
Think about all the times that you and your doctor or nurse practitioner talked about HIV 
medications since you were diagnosed. 
 
O1. Has your doctor or nurse practitioner ever recommend that you start taking HIV medications 
and you decided that it was not the right time for you? 
 No  (skip to O2) Yes 
 
O1a. On how many separate occasions has your doctor or nurse practitioner discussed the need 
for you to begin HIV medications and you decided not to? 
#_   
 
O2. Thinking again about the time since you very first started taking HIV meds, have you ever 
stopped taking one or more of your meds for any reason? 
 No  (skip to O3) Yes 
 
O2a. On how many separate occasions have you stopped taking one or more of your HIV meds 
for more than a day? 
#_   
 
O2b. On how many of these occasions was your decision to stop based on a recommendation 
from your HIV doctor? 
#_   
 
O2c. On how many of these occasions did you decide not to tell your doctor or nurse practitioner 
that you had stopped taking one or more of your HIV meds? 
#_   
 
O3. Some people we have talked to say that they sometimes take “medication vacations” 
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– meaning that they decide to take a break from taking some or all of their medication for a 
period of time. 
 
Since you started HIV meds, have you ever taken a break from your meds, even for just one day? 
1 No (Skip to O3b) 2 Yes 
 
O3a. How many separate times have you taken a break from your HIV meds for one or more 
days 
(Go to O3c) O3b. Even if you haven’t actually taken a break from your HIV meds, how often do 
you think of taking a break? 
1 Almost everyday 
2 At few times a month  
3 A few times a year 
4 A few times ever  
5 Never 
 
O3c. Have you ever discussed taking a break from your meds with your doctor or nurse?  
1 No 2 Yes 
 
Instructions 
Some people we have talked to say that sometimes they make small adjustments to how they take 
their HIV medications because they are having side effects, because they had a change in their 
plans for the day, they were feeling depressed, or for other reasons. 
 
O4a. Since you started taking HIV medications, have you ever… 
…taken less of a medication than was prescribed? Yes No 
 
O4b. Since you started taking HIV medications, have you ever… 
…taken a medication dose significantly later than you had scheduled?  Yes No 
 
O4c. Since you started taking HIV medications, have you ever… 
…taken two doses at the same time to make up for a previous missed dose? Yes No 
 
O4d. Since you started taking HIV medications, have you ever… 
…skipped the special instructions for your medication, like “with meals”, “on an empty  
stomach”, “every 8 hours”, or “with plenty of fluids” Yes No 
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Appendix D. 
Last Month Adherence 
Instructions. For the next question, please look at HANDOUT A. 
 
Put a mark on the line below at the point that shows your best guess about how much of your 
prescribed HIV medication you have taken in the last month. We would be surprised if this were 
100% for most people. 
For example:   
0% means you have taken no medication 
50% means you have taken half your medication 
100% means you have taken every single dose of your medication Click ‘Continue’ once  
Instructions. For this question, please look at HANDOUT B. Again, there is a scale marked 0 
to 100. 
Put a mark on the line below at the point that shows your best guess about how often you made 
small adjustments in how you take your HIV meds over the past month. We would be surprised 
if this were 0% for most people. 
 
For example:  0% means you never make small adjustments to your regimen 50% means you 
make small adjustments about half the time 100% means that you always make small adjustments 
to your regimen 
 
Click 'Continue' once you have completed HANDOUT B. 
 
Instructions. For this question, please look at the scale on HANDOUT C. 
 
Some people we have talked to say that they sometimes skip a dose of their HIV medication for 
personal reasons. 
 
In the past month, HOW OFTEN have you skipped a dose of your HIV meds because you were 
having side effects, had a change in your plans, felt depressed, or for some other reason? 
 
For example: 
100% means you skipped every dose of your meds.  
50% means that you skipped about half of your doses 
0% means that you never skipped a dose in the past month Click 'Continue' once you have 
completed 
 
OK, you’ve made it to the last questions about your meds! Great work! 
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Appendix E. 
 
Past week Adherence 
For this last section, please look at the calendar that you filled out with the research assistant just 
a few minutes ago. Remember that you filled in the number of pills that you are supposed to take 
for your HIV for each day in the past week. 
 
O5a. How many of your pills did you forget to take OR decide to skip on DAY 1? 
O5b. Day 2 
O5c. Day 3 
O5d. Day 4 
O5e. Day 5 
O5f. Day 6 
O5g. Day 7 
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HANDOUT A 
 
Put a mark on the line below at the point that shows your best guess about how much of your prescribed HIV medication you have 
taken in the last month. We would be surprised if this were 100% for most people. 
 
Examples: 0% means you have taken no medication 
50% means you have taken half your medication 
100% means you have taken every single dose of your medication 
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HANDOUT B 
 
Put a mark on the line below at the point that shows your best guess about how often you made small adjustments in how you 
take your HIV meds over the past month. We would be surprised if this were 0% for most people. 
 
Examples: 0% means you never make small adjustments to your 
regimen 50% means you make small adjustments about 
half the time 
100% means that you always make small adjustments to your regimen 
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HANDOUT C 
 
Put a mark on the line below at the point that shows your BEST GUESS about how often in the past month you skipped a dose of 
your HIV meds because you were having side effects, had a change in your plans, felt depressed, or for some other reason. We would 
be surprised if this were 0% for most people. 
 
Examples: 100% means you skipped every dose of your meds. 
50% means that you skipped about half of your doses 
0% means that you never skipped a dose in the past month 
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Appendix F. 
Demographic & Health History Questions 
A1. What is your gender? 1  Female  2  Male  3  Transgender 
A2. How old are you?             _____ years old 
A3a. In what year were you born?      ______ 
A3b. In what month were you born?  ______ 
A3c. On what day of the month were you born? _____  
A4. What is the highest level of education that you have completed? 
 1  Less than high-school 
 2  High-school diploma or GED 
 3  Some college 
 4  Associates degree or Technical Certification 
 5  Bachelors degree 
 6  Masters degree 
 7  Doctoral degree 
A5. Which of the following BEST describes your racial/ethnic background? Is it… 
 1  Native Hawaiian or Other Pacific Islander 
2  Black or African-American  
 3  White/Caucasian  
 4  Asian 
5  American Indian or Alaska Native 
 6  Mixed or Multi-racial  
A6. Do you consider yourself to be Hispanic/Latina/Latino? 
 1  No   2  Yes 
A7.  Which of the following statements applies best to you? 
 1  I am sexually attracted to men. 
 2  I am sexually attracted to men and women. 
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 3  I am sexually attracted to women.   
A8.   Which best describes your current relationship status? 
 1  In a committed relationship 
 2  Single and dating one or more people 
 3  Single and interested in dating but not currently dating  
 4  Single and not interested in a relationship at all 
A9.  Are you married? 
 1  No   2  Yes 
A10.  Is English your first language?    
 1  No   2  Yes 
A11. Are you currently employed? 
 1  No (skip to A12)  2  Yes (go to A11a)   
 A11a. On average, how many hours per week do you work? 
  1  Less than 10 hours 
  2  10 – 20 hours 
  3  21 – 39 hours 
  4  40+ hours 
A12. Approximately how much money do you have to live off of in an average MONTH?  
This includes money that goes toward paying your rent, utilities, and other monthly bills.  
Monthly income: $ ________  
A13.  From which of the following sources do you regularly receive income?  (check all that 
apply) 
 1  Wages or salary from job 
 2  Unemployment 
 3  Welfare 
 4  Disability  
 5  Spouse/Partner 
 6  Family 
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 7  Friends  
A14. In what year were you diagnosed with HIV?  _______ 
A15. What was your most recent viral load result? 
1  Undetectable 
2  Detectable 
3  Don’t know 
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